+

WO2001063293A8 - Diagnosis and treatment of schizophrenia - Google Patents

Diagnosis and treatment of schizophrenia

Info

Publication number
WO2001063293A8
WO2001063293A8 PCT/GB2001/000783 GB0100783W WO0163293A8 WO 2001063293 A8 WO2001063293 A8 WO 2001063293A8 GB 0100783 W GB0100783 W GB 0100783W WO 0163293 A8 WO0163293 A8 WO 0163293A8
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
spis
treatment
diagnosis
detectable
Prior art date
Application number
PCT/GB2001/000783
Other languages
French (fr)
Other versions
WO2001063293A3 (en
WO2001063293A2 (en
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Application filed by Oxford Glycosciences Uk Ltd, Herath Mudiyanselage At Herath, Rajesh Bhikhu Parekh, Christian Rohlff filed Critical Oxford Glycosciences Uk Ltd
Priority to EP01905991A priority Critical patent/EP1259818A2/en
Priority to AU2001233954A priority patent/AU2001233954A1/en
Publication of WO2001063293A2 publication Critical patent/WO2001063293A2/en
Publication of WO2001063293A8 publication Critical patent/WO2001063293A8/en
Publication of WO2001063293A3 publication Critical patent/WO2001063293A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid.
PCT/GB2001/000783 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia WO2001063293A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01905991A EP1259818A2 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia
AU2001233954A AU2001233954A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004415.6 2000-02-24
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
US75039500A 2000-12-28 2000-12-28
US09/750,395 2000-12-28

Publications (3)

Publication Number Publication Date
WO2001063293A2 WO2001063293A2 (en) 2001-08-30
WO2001063293A8 true WO2001063293A8 (en) 2001-10-18
WO2001063293A3 WO2001063293A3 (en) 2002-04-11

Family

ID=26243725

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2001/000783 WO2001063293A2 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia
PCT/GB2001/000792 WO2001062785A2 (en) 2000-02-24 2001-02-23 Protein and gene and their use for diagnosis and treatment of schizophrenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000792 WO2001062785A2 (en) 2000-02-24 2001-02-23 Protein and gene and their use for diagnosis and treatment of schizophrenia

Country Status (3)

Country Link
EP (2) EP1259818A2 (en)
AU (2) AU2001237543A1 (en)
WO (2) WO2001063293A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408333A3 (en) * 2001-10-03 2006-10-25 Pfizer Products Inc. Diagnosis and treatment of Alzheimer's disease
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
JP2005518443A (en) 2002-02-21 2005-06-23 クォーク バイオテック インコーポレーティッド Method for preventing or treating cerebral ischemia or brain injury
CN1300588C (en) * 2005-02-28 2007-02-14 上海交通大学 Method for acquiring plasma specific protein for schizophrenia diagnosis and use thereof
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
CA2748449A1 (en) 2008-12-27 2010-07-15 Pawan Saharan Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp
AU4480997A (en) * 1996-09-13 1998-04-02 Mount Sinai School Of Medicine Of The City University Of New York, The Screening methods for compounds useful in the treatment of schizophrenia
AU6465798A (en) * 1997-03-14 1998-09-29 Neuromark Diagnosing neurologic disorders
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
WO1999011796A1 (en) * 1997-09-05 1999-03-11 Acorda Therapeutics Hnk-1 sulfotransferase and methods of use therefor
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU7508100A (en) * 1999-10-04 2001-05-10 Jens Andersen Human seizure related proteins
EP1101820A1 (en) * 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
WO2001063293A3 (en) 2002-04-11
EP1259818A2 (en) 2002-11-27
EP1259607A2 (en) 2002-11-27
WO2001062785A2 (en) 2001-08-30
AU2001237543A1 (en) 2001-09-03
AU2001233954A1 (en) 2001-09-03
WO2001063293A2 (en) 2001-08-30
WO2001062785A3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
DE69933661D1 (en) GENOMIC SEQUENCE OF THE 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP), POLYMORPHIC MARKERS AND THEIR USE IN THE DIAGNOSIS OF ASTHMA
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2002082075A3 (en) Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
DE69937368D1 (en) PROBATION OF KIDNEY DISEASES AND TREATMENT
ATE353974T1 (en) METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
ATE419516T1 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
WO1999047925A3 (en) Methods and compositions for diagnosis of rheumatoid arthritis
WO2001013117A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2002090974A3 (en) Method for detecting progredient chronic dementia, and associated peptides and detection reagents
DE60125537D1 (en) COMPOSITION FOR DIAGNOSIS AND TREATMENT OF HERPES SIMPLEX VIRUS INFECTIONS
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
EP1283272A3 (en) Methods and means for assessing HIV envelope inhibitor therapy
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2003048734A3 (en) Detection of matrix metalloproteinase rna in plasma and serum
HUP0101285A2 (en) Methods and compositions for diagnosis of hepatoma
ATE255229T1 (en) DPI-6, A THERAPEUTIC BIOMARKER IN NEUROLOGICAL DISEASES
WO2002054080A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2001 UNDER (30) REPLACE "28.02.2000" BY "28.12.2000"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001905991

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001905991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001905991

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载